Wall Street analyst estimates for Quantum BioPharma Ltd. (QNTM): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-06 | $-0.50 | ||
| 2026-08-13 | $-0.47 | $-0.42 | -11.9% |
| 2026-05-07 | $-3.06 | $-0.41 | -643.4% |
| 2026-03-27 | $-0.19 | $-1.02 | +81.2% |
| 2025-11-07 | $-1.25 | $-0.20 | -525.0% |
| 2025-08-06 | $-3.23 | $-0.17 | -1800.0% |
| 2025-05-14 | $-1.41 | $-0.37 | -281.1% |
| 2025-03-28 | $-2.89 | $-0.80 | -261.2% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | $20630 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | $182612 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | $20630 | -$182612 | -$2.6M | 0 | 0 | 0 | 0 | 0 | 0 |
| Research & Development | 0 | 0 | 0 | 0 | $7.8M | $6.3M | $6.9M | $3.9M | $6.1M | $2.8M |
| Selling, General & Admin | $29628 | $2.8M | $17.5M | $20.5M | $18.1M | $23.4M | $16.0M | $13.2M | $9.3M | $12.0M |
| Operating Expenses | $177984 | $2.8M | $18.6M | $30.0M | $30.7M | $33.7M | $27.4M | $23.8M | $16.1M | $15.3M |
| Operating Income | 0 | -$2.8M | 0 | -$30.6M | -$30.7M | -$33.7M | -$27.4M | -$23.8M | -$16.1M | -$15.3M |
| EBITDA | -$29628 | -$2.8M | -$16.5M | -$32.0M | -$24.3M | -$29.8M | -$22.1M | -$15.7M | -$14.4M | -$25.8M |
| Interest Expense | 0 | 0 | 0 | $155316 | $235581 | $69404 | $48822 | $299 | $47577 | $618640 |
| Pre-tax Income | -$29628 | -$2.8M | -$16.7M | -$46.5M | -$28.5M | -$33.9M | -$26.7M | -$18.2M | -$14.9M | -$27.0M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$29628 | -$2.8M | -$22.6M | -$39.1M | -$31.8M | -$35.3M | -$23.6M | -$17.9M | -$14.2M | -$26.2M |
| EPS | $-0.29 | $-27.75 | $-183.54 | $-360.45 | $-171.62 | $-65.63 | $-39.62 | $-29.39 | $-12.49 | $-8.11 |
| EPS (Diluted) | $-0.29 | $-27.75 | $-183.54 | $-360.45 | $-171.62 | $-65.63 | $-39.62 | $-29.39 | $-12.49 | $-8.11 |
| Shares Outstanding (Diluted) | $101000 | $101000 | $90848 | $108557 | $185291 | $537618 | $595882 | $609056 | $1.1M | $3.3M |
Price
| Price | $3.65 |
| Market Cap | $23M |
| Exchange | NASDAQ |
| Country | CA |
Related companies: ANVS · ATNM · BCAB · CELU · CPIX · EVAX · PYPD
Explore sector: Healthcare · Biotechnology
More sections of QNTM: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks